抑郁症患者血清IL-1β、IL-6水平及认知行为干预的研究

Study on serum levels of IL-1β and IL--6 in patients with depression treated with paroxetine and cognitive--behavior intervention

目的初探抑郁症患者认知行为干预与细胞免疫功能异常的关系。方法采用酶联免疫吸附法（ELISA）检测25名采用认知行为干预联合帕罗西汀治疗及25名单用帕罗西汀治疗的抑郁症治疗前后与20名健康对照的血清白介素-1β（IL-1β）及白介素-6（IL-6）水平。结果两组抑郁症患者治疗前血清IL-1β和IL-6水平显著高于对照组（P〈0．01），治疗后与对照组无明显差异（P〉0．05）；治疗后两组抑郁症患者血清IL-1β和IL-6水平差异无显著性意义（P〉0．05）。结论抑郁症存在免疫激活现象，心理治疗联合药物治疗抑郁症疗效优于单用药物治疗，两种治疗方法均可使IL-1β和IL-6水平降低。

Objective To explore the relationship between the Cognitive--behavior intervention and dysfunction of cellular immunity in patients with depression. Methods Enzyme--linked Immunosorbent Assays （ELISA） was used to measure the serum levels of IL-1β and IL-6 in 25 depressive patients treated with paroxetine combined with Cognitive- behavior intervention （group A） and another 25 depressive patients treated with paroxetine alone （group B） and 20 healthy controls （group C）. Results The study showed that before the treatment, the serum levels of IL-- 1β and IL - 6 in groups A and B were significantly higher than that in the control group （P 〈 0.01）. After a 4--week treatment, however, no significant difference was found in the serum levels of IL--1β and IL - 6 between the groups （P 〈 0.05）. Conclusions The results suggest that there is immune activation in depression. Psychotherapy combined with paroxetine is more effective for depression than medication alone, and both can reduce the levels of IL-1β and 1L-6.